Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 3718 | 3.195 |
09:34 ET | 220 | 3.1636 |
09:36 ET | 1430 | 3.17 |
09:38 ET | 400 | 3.17 |
09:39 ET | 1372 | 3.1429 |
09:41 ET | 418 | 3.1586 |
09:43 ET | 1700 | 3.17 |
09:45 ET | 300 | 3.2 |
09:48 ET | 1354 | 3.17 |
09:50 ET | 100 | 3.16 |
09:54 ET | 3639 | 3.12 |
09:56 ET | 3500 | 3.135 |
09:57 ET | 600 | 3.14 |
09:59 ET | 340 | 3.141 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 171.3M | -0.7x | --- |
Greenwich Lifesciences Inc | 173.9M | -19.7x | --- |
Achieve Life Sciences Inc | 176.9M | -4.1x | --- |
RAPT Therapeutics Inc | 161.1M | -1.5x | --- |
Outlook Therapeutics Inc | 186.4M | -0.7x | --- |
Trevi Therapeutics Inc | 186.7M | -7.7x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $171.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.42 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.